Antimicrobial sensitisers: Gatekeepers to avoid the development of multidrug-resistant bacteria

  26 March 2024

Multidrug-resistant bacteria’s resistance to antibiotics necessitates the development of new antibacterial agents, but high costs and timeframes limit their development. The concept of “antibiotic adjuvant” has limited drug development speed. This review article introduces the concept of non-self-antimicrobial sensitisers (NSAS), distinguishing it from antibiotic adjuvants. It discusses scientific methods to restore bacterial sensitivity to antibiotics, sources, and action mechanisms of existing NSAS, guiding further research.

Author(s): Hanfei Wang et al
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed